Shares of Hims &amp; Hers Health Inc (NYSE:HIMS) tanked in early trading on Tuesday, after the company Monday reported disappointing first-quarter results.



Here are the key analyst insights:



<ul>
<li>JPMorgan analyst Cory Carpenter reiterated an Overweight rating, while cutting the price target from $35 to $33.</li>



<li>Needham analyst Ryan MacDonald maintained a Buy rating, while lifting the price target from $30 to $35.</li>



<li>BTIG analyst David Larsen reaffirmed a Neutral rating on the stock.</li>
</ul>



Check out other analyst stock ratings.



JPMorgan: Hims &amp; Hers Health reported mixed results, amid &#34;noise&#34; created by the shift from compounded to Novo-branded GLP-1s (glucagon-like peptide-1 receptor agonists), Carpenter said in a note. The company reported revenue of $608 million, representing 4% year-on-year growth, which was &#34;no worse than feared,&#34; while strong Wegovy uptake led management to raise their 2026 revenue outlook, he added.



Hims &amp; Hers Health guided to second-quarter revenue of $680-$700 million, representing 27% year-on-year growth, while raising the 2026 revenue outlook from $2.7-$2.9 billion to $2.8-$3.0 billion, the analyst stated. While the 2026 EBITDA outlook was lowered by $25 million, stroking concerns over the shift to branded impacting the company's margins, management said the reduction was due to &#34;transitory factors,&#34; he further wrote.



Needham: Hims &amp; Hers Health reported revenue of $608.1 million and adjusted EBITDA of $44.3 million, missing consensus estimates of $617 million and $47 million, respectively, MacDonald said. Subscribers grew 9.2% year-on-year and 2.9% sequentially to 2.584 million, he added.



The renewed partnership with Novo Nordisk (NYSE:NVO) is triggering strong demand, and Hims &amp; Hers Health is on track to add 100,000 new weight-loss subscribers per month, the analyst stated. The Novo partnership helps to bring in numerous net new subs for HIMS to create “cross-sell multiple categories of care like labs, testosterone and menopause care,&#34; he further wrote.



BTIG: Hims &amp; Hers Health's adjusted EBITDA contracted by 51% year-on-year to $44.3 million and fell significantly short of expectations. The company also raised its 2026 revenue outlook. However, management reduced adjusted EBITDA guidance from $300-$375 million to $275-$350 million.



&#34;Our view is that the branded GLP-1s are far lower-margin than the compounded GLP-1s, and the transition to branded products is putting significant pressure on EBITDA,&#34; the analyst wrote.



HIMS Price Action: Shares of Hims &amp; Hers Health had declined by 14.07% to $25.04 at the time of publication on Tuesday.



<div>




Read Also:

Claude Grew 10x Faster Than ChatGPT In April — Is OpenAI Losing AI Power Users?




</div>


Image: Shutterstock

HIMS

HIMY

HIMZ

Hims & Hers Health reported disappointing Q1 results, leading to a 14.07% drop in shares. Revenue was $608 million, missing estimates, while EBITDA fell to $44.3 million. Analysts had mixed reactions: JPMorgan maintained an Overweight rating but lowered the price target to $33; Needham kept a Buy rating and raised the target to $35; BTIG reaffirmed a Neutral rating. The company raised its 2026 revenue outlook despite lowering EBITDA guidance by $25 million, citing concerns over margin pressure from the shift to branded GLP-1s.

Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts